MannKind Corporation
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a MNKD research report →
Companywww.mannkindcorp.com
MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes. It also promotes Thyquidity to adult and pediatric endocrinologists, and other healthcare providers for the treatment of hypothyroidism.
- CEO
- Michael E. Castagna
- IPO
- 2004
- Employees
- 403
- HQ
- Danbury, CA, US
Price Chart
Valuation
- Market Cap
- $1.00B
- P/E
- -41.89
- P/S
- 2.78
- P/B
- -16.92
- EV/EBITDA
- 48.70
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 75.96%
- Op Margin
- 3.71%
- Net Margin
- -6.63%
- ROE
- 45.59%
- ROIC
- 1.80%
Growth & Income
- Revenue
- $348.97M · 22.23%
- Net Income
- $5.86M · -78.75%
- EPS
- $0.02 · -80.00%
- Op Income
- $38.80M
- FCF YoY
- -58.29%
Performance & Tape
- 52W High
- $6.51
- 52W Low
- $2.23
- 50D MA
- $2.76
- 200D MA
- $4.57
- Beta
- 1.04
- Avg Volume
- 6.89M
Get TickerSpark's AI analysis on MNKD
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| May 11, 26 | Tross Stuart A | other | 8,073 |
| May 11, 26 | Binder Steven B. | other | 5,560 |
| May 12, 26 | Binder Steven B. | sell | 16,940 |
| May 11, 26 | Castagna Michael | other | 34,957 |
| May 11, 26 | Thomson David | other | 12,387 |
| May 12, 26 | Thomson David | sell | 3,033 |
| Mar 10, 26 | Castagna Michael | other | 0 |
| Apr 22, 26 | Prentiss Christopher B | other | 12,267 |
| Mar 23, 26 | Prentiss Christopher B | other | 221,000 |
| Mar 23, 26 | Prentiss Christopher B | other | 217,000 |
Our MNKD Coverage
We haven't published any research on MNKD yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate MNKD Report →